Cellular Biology |
From the Division of Stroke and Vascular Disease, St. Boniface General Hospital Research Centre, and Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Correspondence to Grant N. Pierce, PhD, FACC, Director, Division of Stroke and Vascular Disease, St. Boniface General Hospital Research Centre, 351 Tache Ave, Winnipeg, Manitoba, Canada R2H 2A6. E-mail pierce{at}sbrc.umanitoba.ca
| Abstract |
|---|
|
|
|---|
Key Words: oxidized LDL vascular smooth muscle cell atherosclerosis Ca2+ sarcoplasmic reticulum
| Introduction |
|---|
|
|
|---|
The current concept regarding the development of atherosclerosis is dominated by the assumption that the accumulation of lipids is the primary risk factor. Less research attention has been directed toward the role of calcium in this process. However, a significant increase in cellular calcium has been identified in atherosclerotic vessels.5 The increase in cell calcium is thought to be involved in several important processes associated with atherosclerosis. These include abnormalities in VSMC contraction and proliferation, excessive secretion of extracellular matrix proteins (such as collagen, elastin, and proteoglycans), secretion of chemoattractants and growth factors, and platelet aggregation.6 7
Recently, several studies have demonstrated that an acute administration of oxLDL generates a Ca2+ transient in different cell types (for review, see Reference 88 ). The ability for a single exposure of oxLDL to generate a rapid Ca2+ transient was suggested to be important in atherosclerosis. However, this stimulatory effect of an acute exposure of oxLDL on VSMC [Ca2+]i appears to be in conflict with many studies that have shown arterial smooth muscle to be unresponsive to a variety of vasoactive agents under atherosclerotic conditions.9 10 11 12 The discrepancy may be due to the time of exposure of VSMCs to oxLDL. Atherosclerosis is a relatively slow, gradual process. It may be more relevant to this disease state to selectively examine the cellular effects of oxLDL, an important atherosclerotic factor, over a period of time. The purpose of this study, therefore, was to determine the effect of oxLDL on [Ca2+]i in VSMCs that have been chronically incubated with low [oxLDL]. Surprisingly, our results demonstrate that cells become nonresponsive to oxLDL after they are incubated for extended periods of time with oxLDL. This is accompanied by a striking change in inositol 1,4,5-trisphosphate (IP3) receptor density in VSMCs. This change is also observed in situ in the atherosclerotic plaques obtained from cholesterol-fed rabbits.
| Materials and Methods |
|---|
|
|
|---|
The EDTA concentration in native LDL was reduced before LDL oxidation.
Native LDL was diluted 10-fold in 150 mmol/L NaCl (pH 7.4) and
oxidized by incubation with a solution of 50 µmol/L
FeCl3 and 0.25 mmol/L ADP for 3 hours at
37°C. The extent of LDL oxidation was evaluated by (1) measurement of
thiobarbituric acid reactive substances,13 15 (2)
electrophoretic mobility on agarose gels (using the Chiron
Diagnostic Lipoprotein System), and (3) measurement of
-tocopherol content by high-performance liquid
chromatography.16
Vascular Smooth Muscle Cells
An explant technique was used to generate primary cultures of
VSMCs from normal rabbit thoracic aorta.17 The
aorta from a male New Zealand White rabbit (2.5 to 3 kg body weight)
was isolated and cleaned of excess fat and connective tissue. The aorta
was cut into 2- to 3-mm sections and transferred to a culture dish with
growth medium (20% FBS in DMEM) and 5% antibiotic antimycotic (Gibco
BRL). The explants were incubated in a humidified incubator
equilibrated with 5% CO2 and maintained at
37°C. Initial migration of VSMCs was observed within the first 6
days. After 7 days of migration, these explants were transferred to a
new culture dish for further migration. VSMCs from the second phase of
migration were used in our experiments. To induce differentiation,
VSMCs were placed (for 5 to 6 days) in a serum-free medium as
described.18
Chronic Treatment of VSMCs With oxLDL
VSMCs used in our experimental protocol were from either the
first or second passage. The cells were serum-starved for 6 days before
exposure to oxLDL. In chronic experiments, VSMCs were exposed for a
period of 6 days to different concentrations of freshly prepared oxLDL
(0.001 to 0.025 mg cholesterol/mL LDL). The medium
containing freshly oxidized LDL was added daily to the cultured cells.
The control cells were also kept in culture for the same length of time
as the treated cells. The cytotoxicity of different concentrations of
oxLDL was assessed by two tests: (1) lactate dehydrogenase (LDH)
released into the culture medium19 and (2) ethidium
homodimer staining of cell nuclei (Viability/Cytotoxicity Assay Kit,
Molecular Probes).
IP3 Content
VSMCs with and without treatment with oxLDL were washed with
ice-cold PBS, then scraped down and homogenized. This
homogenate was used to measure D-myo-inositol
1,4,5-trisphosphate (IP3) content in VSMCs with a
radioisotopic assay kit (Amersham).
Immunocytochemistry
VSMC phenotype was identified using monoclonal
antibodies against smooth muscle
-actin, myosin, and caldesmon
(Sigma-Aldrich). For the identification of IP3
receptors within VSMCs, quiescent cells were fixed and incubated with
monoclonal anti-IP3 receptor antibodies that
recognize all 3 types of IP3 receptors (ie, type
I, II, and III) (Calbiochem). These cells were further incubated with a
secondary antibody conjugated to FITC. The fluorescent images
were obtained with a Bio-Rad MRC-600 confocal system.
Immunohistochemistry
The aortas from both control and 0.5%
cholesterol-fed (12- to 14-week diet) male New Zealand
White rabbits were cut into 5-mm sections and placed in a mold covered
with O.C.T. embedding compound (Sakura Finetek, Torrance, Calif). These
molds were frozen and cut into 7-µm sections using a Leitz 1720
Cryostat. Before use, these slides were fixed in 1:1 solution of
acetone and methanol (-20°C) for 15 minutes. These sections were
then blocked with 5% skim milk and incubated with monoclonal
anti-IP3 receptor antibody (1:100) overnight at
4°C. The aortic sections were then incubated with anti-mouse IgG
biotinylated whole antibody (from goat) (1:20) followed by streptavidin
conjugated to Texas Red (1:20) (Amersham). Rabbits were obtained
from local suppliers and maintained in the Animal Care Facility at St.
Boniface Hospital Research Centre under the guidelines of the Canadian
Council on Animal Care.
Western Blotting
After treatment of VSMCs with oxLDL, cells were lysed with lysis
buffer (1% SDS, 100 mmol/L NaCl, 62.5 mmol/L Tris-HCl [pH
7.6], 1 mmol/L PMSF, and 10 µg/mL leupeptin). Cell extracts
were denatured with sample buffer (62.5 mmol/L Tris-HCl, 1% SDS,
10% glycerol, 0.01% bromophenol blue, and 20 µg/mL
ß-mercaptoethanol) at 100°C for 5 minutes. The samples were
separated on a 6% SDS polyacrylamide gel and transferred
electrophoretically onto a polyvinylidene difluoride membrane
before incubating with a polyclonal anti-IP3
receptor antibody (Chemicon International Inc). The blots were
incubated with HRP-conjugated goat anti-rabbit IgG. The
IP3 receptor was detected with Pierce Super
Signal detection system.
Calcium Measurements
Measurement of [Ca]i in a single cell
was carried out using a Spex spectrofluorometer, as described in detail
previously.13 20 Cultured VSMCs were loaded with 2
µmol/L fura-2 for 20 minutes at 22°C in a Krebs-Henseleit buffer
(in mmol/L: NaCl 120, NaHCO3 25, KCl 4.8,
KH2PO4 1.2,
MgSO4 1.25, CaCl2 1.8, and
dextrose 8.6). The fluorescent intensities of fura-2, which
reflects bound and unbound calcium, were determined by exciting the
cell at 340 and 380 nm and recording emission at 505 nm. The
maximum and minimum fluorescence signals were obtained by
adding 10 µmol/L 4-Bromo-A23187 and 5 mmol/L EGTA,
respectively, at the end of the experiment to calibrate the signal with
the
[Ca2+]i.21
Statistical Analysis
Data were expressed as mean±SE. The statistical comparisons
were made using one-way analysis of variance, followed by the
Student-Newman-Keuls test for multiple comparison. Differences between
means were considered significant at P<0.05.
| Results |
|---|
|
|
|---|
We first examined the effects of a concentration of oxLDL
frequently used in other studies for the cellular effects of
oxLDL.8 As shown in Figure 1
, 0.1 mg/mL oxLDL caused a rapid
increase in Ca2+i. The peak
increase in Ca2+i was observed
within 5 to 10 seconds of exposure to oxLDL. The Fe-ADP free radical
generating system did not have any effect on
Ca2+i by itself. Native LDL
elicited either no change or a modest increase in the
Ca2+ transient in VSMCs (data not shown).
Removing oxLDL from the solution bathing the VSMCs (Figure 1A
)
could eliminate the effects of oxLDL on
Ca2+i. The increase in
[Ca2+]i induced by 0.1
mg/mL oxLDL was also observed in a calcium-free solution (Figure 1B
). Therefore, the increase in
Ca2+i induced by oxLDL likely
resulted from a release of Ca2+ from the
sarcoplasmic reticulum (SR). This increase in
[Ca2+]i in response to
oxLDL occurred in all cells irrespective of the basal
[Ca2+]i.
|
Ca2+ release from the SR can occur via an
IP3 signaling mechanism.22
Therefore, oxLDL was tested for its capacity to increase VSMC
IP3 levels. The basal IP3
concentration was
20 pmol/mg protein. The IP3
levels in VSMCs acutely exposed to 0.1 mg/mL oxLDL for 20 seconds
increased by
5 fold (Figure 2
).
To further identify the potential signaling pathway through which oxLDL
acted to cause a release of calcium from the SR, we used NCDC,
which disrupts the phosphatidylinositol cascade in the cell via an
inhibition of phospholipase C.23 In 5 separate cell
experiments, two cells exhibited a small, delayed response to oxLDL in
the presence of NCDC (as shown in one representative
experiment in Figure 3
). NCDC-treated
cells were completely unresponsive in 3 other cases. Incubation of
VSMCs with 50 µmol/mL NCDC blocked IP3
formation even after stimulation with 0.1 mg/mL oxLDL (Figure 2
).
|
|
Chronic Exposure of VSMCs to oxLDL
What Effect Does Chronic Exposure of VSMCs to oxLDL Have on
Cell Integrity?
Although VSMCs were acutely responsive to oxLDL, these cells may
have a different response after extended exposure to oxLDL in culture.
VSMCs were treated for up to 6 days with concentrations that were up to
100-fold lower than those previously tested in the acute experiments.
The medium was changed daily. This medium contained freshly prepared
oxLDL. Control cells were maintained for the same amount of time in an
identical medium except for the addition of oxLDL.
OxLDL has a cytotoxic effect on cultured cells.24
Therefore, it was important to assess the effect of these
concentrations of oxLDL on the viability of VSMCs. The viability of
VSMCs was tested using the Live/Dead assay and also examined with LDH
release from the cells. Incubation of cells with 0.025 mg/mL oxLDL over
a 6-day period did not induce a cytotoxic effect as determined by the
Live/Dead assay, nor was there a significant release of LDH into the
medium in comparison to control untreated cells (data not shown).
Subsequent experiments, therefore, were undertaken at [oxLDL]
0.025
mg/mL.
Will Chronic Exposure of VSMCs to oxLDL Alter Basal
[Ca2+]?
A small proportion of the VSMCs incubated chronically with oxLDL
exhibited a change in cell morphology to foam cells. These cells were
not the focus of our study. Instead, we chose to investigate
[Ca2+] in cells that maintained the long,
spindle shape that is typical of VSMCs. Cells were incubated with 0.001
to 0.025 mg cholesterol/mL for up to 6 days. The basal
[Ca2+] was not significantly changed among the
different experimental groups (P>0.05).
[Ca2+]i was 182±22
nmol/L (n=24), 154±14 nmol/L (n=32), and 219±19 nmol/L (n=22), for
cells treated with 0, 0.005, and 0.025 mg/mL oxLDL, respectively.
Will Chronic Exposure to oxLDL Alter Cellular Ca2+
Transients in Response to Subsequent Stimulation by oxLDL?
VSMCs were incubated with oxLDL for 6 days, then washed and
examined for their ability to respond with an increase in
[Ca2+]i to an acute
application of 0.1 mg/mL oxLDL. The extended treatment of VSMCs with
different [oxLDL] had a pronounced effect on
Ca2+i regulation. Some, but not
all, of the VSMCs responded to oxLDL with an increase in
Ca2+i. By examining the number
of cells that responded to oxLDL with a rise in
[Ca2+]i in comparison to
the total number of cells tested in each experimental group, a
responder ratio was obtained (Figure 4
).
Less than 10% of VSMCs treated with higher [oxLDL] (0.01 and 0.025
mg/mL) for 6 days subsequently responded to 0.1 mg/mL oxLDL with a
change in Ca2+i. A relatively
low [oxLDL] (0.005 mg/mL) led to a 40% decrease in responder ratio
compared with control. There was no difference in responder ratio
between control VSMCs and the cells chronically treated with 0.001
mg/mL oxLDL.
|
The Ca2+ transient was altered even in the cells
that did respond to oxLDL. As shown in representative
recordings from single cells (Figure 5
), cells responded immediately as a
result of acute stimulation with 0.1 mg/mL oxLDL; however, the peak
response was reduced as the concentration of oxLDL used in the chronic
incubation period increased. VSMCs that were chronically incubated with
higher [oxLDL] (from 0.01 to 0.025 mg/mL) failed to respond to the
calcium mobilizing effect of oxLDL. Data from a large number of
separate experiments were compiled together for analysis
(Table
). The chronic incubation of VSMCs
for 6 days at concentrations of oxLDL as low as 0.005 mg/mL resulted in
a significant blunting of the subsequent effect of oxLDL on
Ca2+i transients. However, it is
also interesting to note that the lowest [oxLDL] tested (0.001 mg/mL)
induced a Ca2+ transient with a half-time that
was approximately twice as long as the control cells (Table
).
|
|
To test whether oxLDL is responsible for the alteration in the Ca2+ transient, we used native LDL in the same chronic setting. VSMCs were treated for 6 days with different concentrations of native LDL (0.001 to 0.025 mg cholesterol/mL). These cells were then stimulated with 0.1 mg/mL oxLDL. All cells responded to oxLDL with a Ca2+ transient (data not shown).
To test the responsiveness of chronically treated cells to other
agonists that target SR calcium release, we used
norepinephrine (
-adrenergic agonist). Binding of
norepinephrine to its
-adrenergic receptor will result
in activation of phospholipase C, formation of
IP3, and
[Ca2+]i release from the
SR. As shown in Figure 6
, control VSMCs
responded to norepinephrine with a rapid increase in
[Ca2+]i, whereas VSMCs
treated with 0.025 mg/mL oxLDL for 6 days failed to show an increase in
[Ca2+]i after exposure to
norepinephrine.
|
What Is the Mechanism Responsible for the Chronic Effects of oxLDL
on VSMC Ca2+?
VSMCs may have lost their capacity to respond to oxLDL with an
increase in Ca2+i because of (1)
a decrease in oxLDL binding to the cell surface or (2) an alteration in
the intracellular signaling, which effected the increase in
Ca2+i. Because the receptors
that regulate oxLDL binding to the cell have not been fully
characterized and because oxLDL may gain access to the cell through
several different receptors, it is impossible to directly assess this
first possibility.25 However, we could address the second
possibility. As demonstrated previously (Figure 2
), the acute
effects of oxLDL on Ca2+i were
likely due to an IP3-mediated release of
Ca2+ from the SR. Therefore, it was reasonable to
hypothesize that an extensive incubation of VSMCs with oxLDL resulted
in a change in the IP3 signaling pathway. VSMCs
were treated with 0.025 mg/mL oxLDL for 3 or 6 days. These cells were
then fixed and treated with a monoclonal antibody against the
IP3 receptor. This anti-IP3
antibody recognizes all 3 known isoforms of the
IP3 receptor (type I, II, and III). However,
because VSMCs contain 73% of type I IP3
receptors, the signal likely emanates mostly from type I
IP3 receptors.26 Figure 7a
through 7c represents results
from control cells. These cells show a high expression of
IP3 receptors in the periphery of the nuclei and
throughout the cytoplasm. VSMCs that were treated with oxLDL for 3 days
(Figure 7d
through 7f) exhibited a small decrease in the density
of IP3 receptors from control. However, a longer
treatment period (6 days) led to a striking reduction in
IP3 receptor density throughout cells (Figure 7g
through 7i). This was quantitated by Western
immunoblots. As shown in Figure 8
, incubation of VSMCs for 6 days with
0.025 mg/mL oxLDL resulted in a significant decrease in
IP3 receptor density. This defect in
IP3 receptor density was accompanied by a
depressed capacity to generate IP3 in cells
chronically exposed to oxLDL (Figure 2
). Thus, chronic exposure
of VSMCs to oxLDL leads to a significant depression in
IP3 signaling in the cells due to an attenuated
generation of IP3 and a decrease in
IP3 receptor density.
|
|
Are the Changes in IP3 Receptor Density Found in
Atherosclerotic Tissue In Situ?
The possibility exists that the cell culture conditions used may
not mimic the in vivo situation in atherosclerosis. It
is unknown whether vascular IP3 receptors are
affected by atherosclerosis. Aortic tissue was removed
from rabbits fed a 0.5% cholesterol-supplemented diet for
12 to 14 weeks. This tissue exhibited gross atherosclerotic plaques.
Sections from these atherosclerotic aorta and control aorta were
examined with immunohistochemical staining for changes in
IP3 receptor density (Figure 9
). IP3 receptors
stained strongly in the medial section of control aorta (Figure 9A
), whereas this staining was reduced in the medial section of
atherosclerotic tissue (Figure 9B
). This difference in
IP3 receptor density was also observed in aortic
sections that contained both plaque and an unaffected area (Figure 9C
). As shown in Figure 9C
, IP3
receptor density was higher in the medial layer of an area with no
plaque, whereas the same medial layer below the plaque region exhibited
a reduction in fluorescence intensity.
|
| Discussion |
|---|
|
|
|---|
Chronic Effects of oxLDL
The effects of oxLDL under acute exposure conditions contrast
sharply with the effects of oxLDL after VSMCs have been chronically
exposed to low [oxLDL]. Chronic exposure of VSMCs to oxLDL resulted
in a loss in the capacity of oxLDL to initiate a
Ca2+ transient. This alteration in
Ca2+ transient was due to the oxidation of LDL,
because native LDL in a similar chronic setting did not show any effect
on the Ca2+ transient. The oxLDL preparation used
in the present study was minimally modified, and the concentrations
used were 10- to 100-fold below those used by many other investigations
that have tested the effects of oxLDL on cell
function.8 27 28 This reinforces the potency that small
quantities of oxLDL have on cell function and emphasizes the potential
pathological significance of the effects observed.
Many studies have implicated oxygen-derived free radicals and oxLDL in the atherosclerotic process.1 2 3 4 Are cells in the area of a developing plaque exposed to oxLDL for extended periods of time? No direct evidence is available; however, indirect evidence would support this contention. For example, the generation of autoantibodies to oxLDL strongly suggests that the oxLDL is present for extended periods of time in the body.29 30 Further, the autoantibody titers correlate with the severity of the plaque formation.30 These findings would suggest that the oxLDL must be elevated chronically. It is also likely that this oxLDL is trapped in the interstitial space and cells would be chronically exposed to it.1 Several other studies have demonstrated that [oxLDL] or its products increase within the plaque as the plaque advances in severity.31 32 These data do not prove that VSMCs or other vascular cells are in contact with oxLDL over extended periods of time, but it is a contention that would be entirely consistent with the general hypothesis of a role for oxLDL in the atherogenic process. Indeed, if one is to assign a role for oxLDL in atherosclerosis, it is far more difficult to argue that cells would be in contact with oxLDL for several minutes in vivo than the contention that cells in a developing atherogenic region are exposed chronically to oxLDL. Our data demonstrate that such conditions have important implications for VSMC function, and that these effects are strikingly different than those previously reported under acute exposure periods.
Several factors may be eliminated in the present study as contributory factors to the effects of oxLDL. For example, this was not due to a cytotoxic effect of the oxLDL. Furthermore, this was not due to a change in VSMC morphology to that of a foam cell. We purposefully examined cells that maintained the spindle-shape morphology that is typical of VSMCs. Interestingly, however, foam cells also failed to elicit a Ca2+ transient in response to any agonist tested (data not shown). This would suggest that oxLDL may induce a transitional change in VSMC function that precedes significant morphological changes.
We have identified one factor that may contribute to the inability of
oxLDL to induce a Ca2+ transient after VSMCs have
been chronically exposed to oxLDL. We have focused our work on the
effects that oxLDL had on intracellular signaling. The present data
strongly suggest that the mechanism responsible for the oxLDL-induced
change in Ca2+ responsiveness within the VSMCs
involves a lesion in IP3 signaling. Because oxLDL
appeared to induce a release of Ca2+ from SR via
an IP3-mediated mechanism under acute exposure
conditions (Figures 1 through 3![]()
![]()
), it is reasonable
to argue that the loss in IP3 receptors under
chronic exposure conditions is at least partly responsible for the
altered Ca2+ transients. Consistent with
this hypothesis, we demonstrate for the first time that
IP3 receptor density is strongly depressed in
VSMCs exposed to oxLDL over time. We cannot rule out an alternative
possibility that oxLDL binding to the VSMCs is depressed after chronic
incubation periods. However, cellular lipid accumulation continues even
in the presence of elevated [oxLDL].1 This would suggest
that the cells have a limited capacity to downregulate oxLDL receptors
and thereby control oxLDL interactions with the cell.1 33
Furthermore, the observation that another agonist
(norepinephrine) that binds to a different surface receptor
than oxLDL but initiates the same IP3 signaling
pathway as oxLDL also is incapable of generating a
Ca2+ transient argues strongly that the primary
defect is the IP3 signaling.
The mechanism responsible for the downregulation in
IP3 receptors is unclear. However, Wojcikiewicz
et al34 demonstrated a downregulation in
IP3 receptor type I as a result of prolonged
exposure of human neuroblastoma to carbachol (a muscarinic agonist).
They suggested that persistent elevation in
[Ca2+]i may be the
mechanism leading to downregulation of these receptors. A similar
downregulation of IP3 receptors and
desensitization of Ca2+ release were also
observed in rat A7r5 aortic smooth muscle cells as the result of
chronic stimulation with vasopressin.35 Their data and
other studies suggested that this downregulation was due to proteasomal
degradation and accelerated proteolysis.35 36 Ultimately,
IP3 generation was also depressed in VSMCs
chronically treated with oxLDL (Figure 2
). This would argue
against an association of elevated
[IP3]i with a
downregulation of IP3 receptors.36
The depression in IP3 generation also suggests an
inhibition of phospholipase C activity by oxLDL over extended periods
of time. Definitive proof of this hypothesis awaits experimental
testing.
Our study also provides important evidence that IP3 receptor density is decreased in vivo in the atherosclerotic plaque. Because the IP3 pathway represents an important mechanism for controlling tension within VSMCs (via its effects on Ca2+), these defects will have important effects on vasoactivity. Our findings agree well with observations that atherosclerosis leaves arterial smooth muscle unresponsive to vasoactive agents.9 10 11 12 The present data demonstrate that cells that are in contact with oxLDL over extended periods of time exhibit an inability to elevate [Ca2+]i to a level that would support normal contractile activity. The lesions identified in IP3 signaling and Ca2+i regulation in the present study would explain the inability of atherosclerotic vessels to exhibit contractile activity in response to vasoactive agents. Our data also demonstrate that these changes in VSMC function precede any transformation in cellular morphology to the foam-cell type that is typical of an atherosclerotic plaque.
[Ca2+i] also has been suggested to play an important role in the development of atherosclerotic plaques. Excessive secretions of extracellular matrix proteins, cytokines, and chemoattractants have been associated with alterations in Ca2+i.6 7 37 Just as important, changes in gene expression, cell growth, and proliferation have been suggested to occur through changes in [Ca2+]i. Our initial studies have indicated that oxLDL is capable of inducing a release of Ca2+ from stores in proximity to the nucleus. This would suggest that oxLDL may be capable of inducing a Ca2+-mediated signal that could participate in nuclear function. Loss of such signaling may have important implications. However, this remains to be studied in detail in the future. The present data, therefore, suggest that the acute capacity of VSMCs to respond to oxLDL may represent an initial signaling response of these cells to the atherogenic environment. This may change dramatically as these cells advance in severity through the various stages of atherosclerosis, ultimately rendering the vessel hyporesponsive to a variety of vasoactive agents. OxLDL may play a key role in changing the Ca2+i regulatory mechanisms in VSMCs during this process.
| Acknowledgments |
|---|
Received January 7, 1999; accepted July 20, 1999.
| References |
|---|
|
|
|---|
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:17851792.
3.
Steinbrecher UP, Parthasarathy S, Leake DS, Witztum
JL, Steinberg D. Modification of low density lipoprotein by
endothelial cells involves lipid peroxidation and
degradation of low density lipoprotein phospholipids. Proc Natl
Acad Sci U S A. 1984;81:38833887.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801809.[Medline] [Order article via Infotrieve]
5.
Strickberger SA, Russek LN, Phair RD. Evidence for
increased aortic plasma membrane calcium transport caused by
experimental atherosclerosis in rabbits. Circ
Res. 1988;62:7580.
6. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249261.[Medline] [Order article via Infotrieve]
7. Phair RD. Cellular calcium and atherosclerosis: a brief review. Cell Calcium. 1988;9:275284.[Medline] [Order article via Infotrieve]
8. Massaeli H, Pierce GN. Involvement of lipoproteins, free radicals, and calcium in cardiovascular disease processes. Cardiovasc Res. 1995;29:597603.[Medline] [Order article via Infotrieve]
9. Yamagishi M, Nissen SE, Booth DC, Gurley JC, Koyama J, Kawano S, DeMaria AN. Coronary reactivity to nitroglycerin: intravascular ultrasound evidence for the importance of plaque distribution. J Am Coll Cardiol. 1995;25:224230.[Abstract]
10. Berkenboom G, Unger P, Fontaine J. Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators. J Cardiovasc Pharmacol. 1989;14(suppl 11):S35S39.
11. Ibengwe JK, Suzuki H. Changes in mechanical responses of vascular smooth muscles to acetylcholine, noradrenaline and high-potassium solution in hypercholesterolemic rabbits. Br J Pharmacol. 1986;87:395402.[Medline] [Order article via Infotrieve]
12.
Verbeuren TJ, Jordaens FH, Zonnekeyn LL, van Hove C,
Coene MC, Herman AG. Effect of
hypercholesterolemia on vascular reactivity in
the rabbi, I: endothelium-dependent and
endothelium-independent contractions and relaxations in
isolated arteries of control and hypercholesterolemic
rabbits. Circ Res. 1986;58:552564.
13.
Liu K, Massaeli H, Pierce GN. The action of oxidized
low density lipoprotein on calcium transients in isolated rabbit
cardiomyocytes. J Biol Chem. 1993;268:41454151.
14.
Liu K, Pierce GN. The effects of low density
lipoprotein on calcium transients in isolated rabbit
cardiomyocytes. J Biol Chem. 1993;268:37673775.
15.
Halliwell B, Chirico S. Lipid peroxidation: its
mechanism, measurement, and significance. Am J Clin
Nutr. 1993;57:715S724S.
16.
Milne DB, Botnen J. Retinol,
-tocopherol, lycopene, and alpha- and beta-carotene
simultaneously determined in plasma by isocratic liquid
chromatography. Clin Chem. 1986;32:874876.
17.
Grünwald J, Haudenschild CC. Intimal injury in
vivo activates vascular smooth muscle cell migration and
explant outgrowth in vitro.
Arteriosclerosis. 1984;4:183188.
18. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217223.[Medline] [Order article via Infotrieve]
19. Bergmeyer HU, Bernt E. Methods of Enzymatic Analysis. New York, NY: Academic Press; 1974:579582.
20. Massaeli H, Pierce GN. Methods for measuring sodium-hydrogen exchange in the heart. In McNeill JH, ed. Biochemical Techniques in the Heart: Methods In Pharmacology. Boca Raton, Fla: CRC Press; 1997:83100.
21.
Grynkiewicz G, Poenie M, Tsien RY. A new generation of
Ca2+ indicators with greatly improved
fluorescence properties. J Biol Chem. 1985;260:34403450.
22. Benevolensky DS, Menshikova EV, Watras J, Levitsky DO, Ritov VB. Characterization of Ca2+ release from the sarcoplasmic reticulum of myocardium and vascular smooth muscle. Biomed Biochim Acta. 1987;46:S393S398.[Medline] [Order article via Infotrieve]
23. Tanaka Y, Hata S, Ishiro H, Ishii K, Nakayama K. Quick stretch increases the production of inositol 1,4,5-trisphosphate (IP3) in porcine coronary artery. Life Sci. 1994;55:227235.[Medline] [Order article via Infotrieve]
24. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 1983;24:10701076.[Abstract]
25.
Lougheed M, Lum CM, Ling W, Suzuki H, Kodama T,
Steinbrecher U. High affinity saturable uptake of oxidized low density
lipoprotein by macrophages from mice lacking the scavenger
receptor class A type I/II. J Biol Chem. 1997;272:1293812944.
26.
De Smedt H., Missiaen L, Parys JB, Bootman MD, Mertens
L, van Den Bosch L, Casteels R. Determination of relative amounts of
inositol trisphosphate receptor mRNA isoforms by ratio polymerase chain
reaction. J Biol Chem. 1994;269:2169121698.
27.
Chen CH, Cartwright J, Li Z, Lou S, Nguyen HH, Gotto-AM
J, Henry PD. Inhibitory effects of
hypercholesterolemia and ox-LDL on
angiogenesis-like endothelial growth in rabbit aortic
explants. Essential role of basic fibroblast growth factor.
Arterioscler Thromb Vasc Biol. 1997;17:13031312.
28. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:7579.
29. van de Vijver L, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 1996;122:245253.[Medline] [Order article via Infotrieve]
30.
Palinski W, Tangirala RK, Miller E, Young SG, Witztum
JL. Increased autoantibody titers against epitopes of oxidized LDL in
LDL receptor-deficient mice with increased
atherosclerosis. Arterioscler Thromb Vasc
Biol. 1995;15:15691576.
31. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta. 1995;1256:141150.[Medline] [Order article via Infotrieve]
32.
Suarna C, Dean RT, May J, Stocker R. Human
atherosclerotic plaque contains both oxidized lipids and relatively
large amounts of alpha-tocopherol and ascorbate.
Arterioscler Thromb Vasc Biol. 1995;15:16161624.
33.
Brown MS, Goldstein JL. A receptor-mediated pathway for
cholesterol homeostasis. Science. 1986;232:3447.
34.
Wojcikiewicz RJ, Furuichi T, Nakade S, Mikoshiba K,
Nahorski SR. Muscarinic receptor activation down-regulates the type I
inositol 1,4,5-trisphosphate receptor by accelerating its degradation.
J Biol Chem. 1994;269:79637969.
35. Sipma H, Deelman L, De Smedt H, Missiaen L, Parys JB, Vanlingen S, Henning RH, Casteels R. Agonist-induced down-regulation of type 1 and type 3 inositol 1,4,5-trisphosphate receptors in A7r5 and DDT1 MF-2 smooth muscle cells. Cell Calcium. 1998;23:1121.[Medline] [Order article via Infotrieve]
36.
Zhu CC, Furuichi T, Mikoshiba K, Wojcikiewicz RJ.
Inositol 1,4,5-trisphosphate receptor down-regulation is
activated directly by inositol 1,4,5-trisphosphate binding.
Studies with binding-defective mutant receptors. J Biol
Chem. 1999;274:34763484.
37. Smirnov VN, Voyno-Yasenetskaya T, Antonov AS, Lukashev ME, Shirinsky VP, Tertov VV, Tkachuk VA. Vascular signal transduction and atherosclerosis. Ann N Y Acad Sci. 1990;598:167181.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. S. Faustino, P. Cheung, M. N. Richard, E. Dibrov, A. L. Kneesch, J. F. Deniset, M. N. Chahine, K. Lee, D. Blackwood, and G. N. Pierce Ceramide regulation of nuclear protein import J. Lipid Res., March 1, 2008; 49(3): 654 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Ander, C. Hurtado, C. S. Raposo, T. G. Maddaford, J. F. Deniset, L. V. Hryshko, G. N. Pierce, and A. Lukas Differential sensitivities of the NCX1.1 and NCX1.3 isoforms of the Na+-Ca2+ exchanger to {alpha}-linolenic acid Cardiovasc Res, January 15, 2007; 73(2): 395 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zorn-Pauly, P. Schaffer, B. Pelzmann, E. Bernhart, G. Wei, P. Lang, G. Ledinski, J. Greilberger, B. Koidl, and G. Jurgens Oxidized LDL induces ventricular myocyte damage and abnormal electrical activity-role of lipid hydroperoxides Cardiovasc Res, April 1, 2005; 66(1): 74 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Zettler, M. A. Prociuk, J. A. Austria, G. Zhong, and G. N. Pierce Oxidized Low-Density Lipoprotein Retards the Growth of Proliferating Cells by Inhibiting Nuclear Translocation of Cell Cycle Proteins Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 727 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hirono, E. Dibrov, C. Hurtado, A. Kostenuk, R. Ducas, and G. N. Pierce Chlamydia pneumoniae Stimulates Proliferation of Vascular Smooth Muscle Cells Through Induction of Endogenous Heat Shock Protein 60 Circ. Res., October 17, 2003; 93(8): 710 - 716. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lipskaia, M.-L. Pourci, C. Delomenie, L. Combettes, D. Goudouneche, J.-L. Paul, T. Capiod, and A.-M. Lompre Phosphatidylinositol 3-Kinase and Calcium-Activated Transcription Pathways Are Required for VLDL-Induced Smooth Muscle Cell Proliferation Circ. Res., May 30, 2003; 92(10): 1115 - 1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Zettler, M. A. Prociuk, J. A. Austria, H. Massaeli, G. Zhong, and G. N. Pierce OxLDL stimulates cell proliferation through a general induction of cell cycle proteins Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H644 - H653. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |